Clinical data | |
---|---|
Trade names | Citanest |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603026 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 55% |
Metabolism | Liver and kidney |
Elimination half-life | 10-150 minutes, longer with impaired liver or kidney function |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.010.871 |
Chemical and physical data | |
Formula | C13H20N2O |
Molar mass | 220.316 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
Melting point | 37 to 38 °C (99 to 100 °F) |
| |
| |
(verify) |
Prilocaine (/ˈpraɪləˌkeɪn/[1]) is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine or EMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).